Vaxcyte Reports Positive OPUS-1 Phase 3 VAX-31 Results

Direct reporting states that Vaxcyte’s pivotal adult Phase 3 OPUS-1 trial of VAX-31 met its prespecified primary endpoints across the studied age groups and had a safety profile similar to the comparator vaccines. This is new, forward-looking clinical evidence with implications for the candidate’s planned regulatory filing and eventual commercialization, warranting the clinical_study classification and approval. The importance score reflects a material pivotal-trial readout that is not yet a regulatory approval; the surprise score reflects that the readout was scheduled, although the positive outcome was not certain. October 5, 2026 is explicit, but no exact event time is provided, so 10:13:20Z is retained as the best estimate based on the contemporaneous report and timestamp confidence is reduced. PCVX, PFE, and MRK are approved because Vaxcyte is directly affected and PCV20 and PCV21 are the comparator products associated with Pfizer and Merck; more indirect service, pharmacy, and less-direct vaccine stakeholders are excluded. The result is distinct from the prior scheduled presentation and matches existing event 7487.